Clinical Trials
6 trialsNCT03624270 2022-10-04
Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia
The University of Hong Kong
Phase 2 Unknown
NCT04869475 2021-05-13
Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation
Ruijin Hospital
Phase 2 Unknown
NCT04695223 2021-01-06
Arsenic Trioxide for Structural p53 Mutations
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT03381781 2018-01-04
Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations
Ruijin Hospital
Phase 2 Unknown
NCT02956772 2017-02-23
Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients
Hunan Provincial People's Hospital
Phase 2 Unknown
NCT00003885 2013-11-06
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
National Cancer Institute (NCI)
Phase 2 Unknown